Tenvir-EM 30 Tablets

babies: it is not applicable. lactating mothers: safe if prescribed.
pregnancy: safe if prescribed. driving: unsafe to use while driving.
alcohol: please consult your doctor before consuming alcohol. liver: safe if prescribed.
kidney: emtricitabine and tenofovir disoproxil fumarate tablets should be used in caution with patients suffering from kidney disease. you may require a dose adjustment and regular monitoring of kidney function.
seek doctor advice before using this medication..

Fatigue Weakness Headache Nausea Diarrhoea Muscle Pain Pain Dizziness Depression.

TENVIR-EM tablet is an antiretroviral agent. it works by preventing hiv (virus) from multiplying.
it also reduces the number of viruses in your body and increases the cd4 cell count in your blood..

If you miss a dose of TENVIR-EM tablet, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• TENVIR-EM tablet is an antiretroviral agent. • emtricitabine and tenofovir disoproxil fumarate tablet is a combination of two medicines that slows down or stops the progression of hiv infections. • it may also be used for preventing hiv and should be started within 72 hours of exposure to hiv. • take it with food, as this increases the absorption of the medicine into the body. • emtricitabine and tenofovir disoproxil fumarate tablet may cause dizziness or sleepiness. do not drive or do anything requiring concentration until you know how it affects you. • skipping doses increases the risk of treatment failure.
make sure that you take all your doses at the correct time. • always practise safe sex while taking emtricitabine and tenofovir disoproxil fumarate tablet. do not share needles or personal items that can have blood or body fluids on them. • it may cause weakening of your bones.
exercise regularly and take calcium and vitamin d supplements as suggested by your doctor..

• (emtricitabine + tenofovir disoproxil fumarate) + tipranavir: concurrent use may decrease the concentration of tenofovir disoproxil fumarate • (emtricitabine + tenofovir disoproxil fumarate) + ritonavir: concurrent use may decrease the concentration of tenofovir disoproxil fumarate • (emtricitabine + tenofovir disoproxil fumarate) + carbamazepine: concurrent use may decrease the concentration of tenofovir disoproxil fumarate • (emtricitabine + tenofovir disoproxil fumarate) + phenobarbital: concurrent use may decrease the concentration of tenofovir disoproxil fumarate • (emtricitabine + tenofovir disoproxil fumarate) + phenytoin: concurrent use may decrease the concentration of tenofovir disoproxil fumarate • (emtricitabine + tenofovir disoproxil fumarate) + rifampin: concurrent use may decrease the concentration of tenofovir disoproxil fumarate • emtricitabine + bortezomib: concurrent use may increase the risk of peripheral neuropathy • emtricitabine + alpha-interferon: concurrent use may increase the risk of lactic acidosis • tenofovir disoproxil fumarate + didanosine: concurrent use may increase the serum concentration of didanosine • tenofovir disoproxil fumarate + atazanavir: concurrent use may decrease the serum concentration of atazanavir • tenofovir disoproxil fumarate + adefovir: concurrent use may decrease the therapeutic effect of adefovir.